215 related articles for article (PubMed ID: 23843040)
1. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation.
Shimoni-Sebag A; Lebenthal-Loinger I; Zender L; Karni R
Carcinogenesis; 2013 Nov; 34(11):2498-504. PubMed ID: 23843040
[TBL] [Abstract][Full Text] [Related]
2. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.
Muñoz Ú; Puche JE; Hannivoort R; Lang UE; Cohen-Naftaly M; Friedman SL
Mol Cancer Res; 2012 Sep; 10(9):1216-27. PubMed ID: 22859706
[TBL] [Abstract][Full Text] [Related]
4. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
Shilo A; Ben Hur V; Denichenko P; Stein I; Pikarsky E; Rauch J; Kolch W; Zender L; Karni R
RNA; 2014 Apr; 20(4):505-15. PubMed ID: 24572810
[TBL] [Abstract][Full Text] [Related]
5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
6. ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf.
Mercer K; Chiloeches A; Hüser M; Kiernan M; Marais R; Pritchard C
Oncogene; 2002 Jan; 21(3):347-55. PubMed ID: 11821947
[TBL] [Abstract][Full Text] [Related]
7. The second RNA-binding domain of the human splicing factor ASF/SF2 is the critical domain controlling adenovirus E1A alternative 5'-splice site selection.
Dauksaite V; Akusjärvi G
Biochem J; 2004 Jul; 381(Pt 2):343-50. PubMed ID: 15068396
[TBL] [Abstract][Full Text] [Related]
8. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
9. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signaling pathway in patients with hepatocellular carcinoma.
Hoffmann K; Shibo L; Xiao Z; Longerich T; Büchler MW; Schemmer P
Anticancer Res; 2011 Nov; 31(11):3883-90. PubMed ID: 22110214
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
Wang Y; Yang J; Gao Y; Zhao XL; Li HZ; Yao Z
Zhonghua Fu Chan Ke Za Zhi; 2009 Jul; 44(7):522-8. PubMed ID: 19957553
[TBL] [Abstract][Full Text] [Related]
11. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.
Ueyama T; Kawashima S; Sakoda T; Rikitake Y; Ishida T; Kawai M; Yamashita T; Ishido S; Hotta H; Yokoyama M
J Mol Cell Cardiol; 2000 Jun; 32(6):947-60. PubMed ID: 10888249
[TBL] [Abstract][Full Text] [Related]
12. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
[TBL] [Abstract][Full Text] [Related]
13. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
Hecquet C; Lefevre G; Valtink M; Engelmann K; Mascarelli F
Invest Ophthalmol Vis Sci; 2002 Sep; 43(9):3091-8. PubMed ID: 12202534
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation.
Shelton JG; Moye PW; Steelman LS; Blalock WL; Lee JT; Franklin RA; McMahon M; McCubrey JA
Leukemia; 2003 Sep; 17(9):1765-82. PubMed ID: 12970777
[TBL] [Abstract][Full Text] [Related]
15. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
17. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells.
Arai A; Aoki M; Weihua Y; Jin A; Miura O
Cell Signal; 2006 Dec; 18(12):2162-71. PubMed ID: 16781119
[TBL] [Abstract][Full Text] [Related]
18. B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis.
Sobczak I; Galabova-Kovacs G; Sadzak I; Kren A; Christofori G; Baccarini M
Oncogene; 2008 Aug; 27(35):4779-87. PubMed ID: 18490924
[TBL] [Abstract][Full Text] [Related]
19. Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways.
Grana TM; Rusyn EV; Zhou H; Sartor CI; Cox AD
Cancer Res; 2002 Jul; 62(14):4142-50. PubMed ID: 12124353
[TBL] [Abstract][Full Text] [Related]
20. Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance.
McCubrey JA; Abrams SL; Ligresti G; Misaghian N; Wong EW; Steelman LS; Bäsecke J; Troppmair J; Libra M; Nicoletti F; Molton S; McMahon M; Evangelisti C; Martelli AM
Leukemia; 2008 Nov; 22(11):2080-90. PubMed ID: 18685611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
